Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med

About 9 months after the FDA OK’d J&J’s 4-in-1 HIV pill Symtuza, the pharma giant rolled out new Phase III data Thursday that demonstrates how newly diagnosed HIV patients are likely to squelch any signs of the virus if they jump on drug within 14 days of diagnosis. And they offered canned tweets in the PR to help spread the word — fast.